Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Equity Ratio (2020 - 2023)

Historic Equity Ratio for Candel Therapeutics (CADL) over the last 4 years, with Q3 2023 value amounting to 0.46.

  • Candel Therapeutics' Equity Ratio fell 2500.45% to 0.46 in Q3 2023 from the same period last year, while for Sep 2023 it was 0.46, marking a year-over-year decrease of 2500.45%. This contributed to the annual value of 0.61 for FY2022, which is 1458.08% down from last year.
  • Per Candel Therapeutics' latest filing, its Equity Ratio stood at 0.46 for Q3 2023, which was down 2500.45% from 0.52 recorded in Q2 2023.
  • In the past 5 years, Candel Therapeutics' Equity Ratio ranged from a high of 0.72 in Q4 2021 and a low of 1.4 during Q2 2021
  • Moreover, its 4-year median value for Equity Ratio was 0.61 (2022), whereas its average is 0.31.
  • As far as peak fluctuations go, Candel Therapeutics' Equity Ratio skyrocketed by 21681.59% in 2021, and later crashed by 2500.45% in 2023.
  • Quarter analysis of 4 years shows Candel Therapeutics' Equity Ratio stood at 0.62 in 2020, then surged by 216.82% to 0.72 in 2021, then decreased by 14.58% to 0.61 in 2022, then decreased by 25.12% to 0.46 in 2023.
  • Its Equity Ratio stands at 0.46 for Q3 2023, versus 0.52 for Q2 2023 and 0.59 for Q1 2023.